Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593175 · ClinicalTrials.gov registry record · Phase 2
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02593175: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02593175 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593175, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes (locally advanced). This treatment study is linked to NCI-2015-00191 protocol, which uses a baseline biopsy to determine the neoadjuvant therapy that matches the sub-type of triple negative breast cancer (TNBC). Immunotherapy with panitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab, carboplatin and paclitaxel before surgery may be an effective treatment for breast cancer by making the tumor smaller and reducing the amount of normal tissue that needs to be removed.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Panitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-11-03 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593175
The ClinicalTrials.gov registry entry for NCT02593175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02593175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593175 about?
NCT02593175 is a clinical study titled "Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC". This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes (locally advanced). This treatment study is linked to NCI-2015-00191 protocol...
What is the current status of trial NCT02593175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-11-03. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT02593175?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593175?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.